{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:44:36Z","timestamp":1770515076894,"version":"3.49.0"},"reference-count":267,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T00:00:00Z","timestamp":1456358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T00:00:00Z","timestamp":1456358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40263-016-0318-7","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T12:04:37Z","timestamp":1456401877000},"page":"245-267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cutaneous Adverse Effects of Neurologic Medications"],"prefix":"10.1007","volume":"30","author":[{"given":"Eman","family":"Bahrani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe E.","family":"Nunneley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph S.","family":"Kass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,25]]},"reference":[{"key":"318_CR1","unstructured":"International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ. Tech Rep Ser. 1972;498:1\u201325."},{"key":"318_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000335612","volume":"97","author":"M Mockenhaupt","year":"2012","unstructured":"Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy. 2012;97:1\u201317.","journal-title":"Chem Immunol Allergy"},{"key":"318_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cger.2013.01.008","volume":"29","author":"AM Ahmed","year":"2013","unstructured":"Ahmed AM, Pritchard S, Reichenberg J. A review of cutaneous drug eruptions. Clin Geriatr Med. 2013;29:527\u201345.","journal-title":"Clin Geriatr Med"},{"key":"318_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3109\/15569527.2012.702837","volume":"32","author":"BG Turk","year":"2013","unstructured":"Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol. 2013;32:41\u20135.","journal-title":"Cutan Ocul Toxicol"},{"key":"318_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0031-6997(24)01501-1","volume":"53","author":"CK Svensson","year":"2001","unstructured":"Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2001;53:357\u201379.","journal-title":"Pharmacol Rev"},{"key":"318_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/978-3-540-29316-3_33","volume-title":"Braun-Falcos dermatol","author":"K Bork","year":"2009","unstructured":"Bork K. Cutaneous adverse drug reactions. In: Burgdorf W, Plewig G, Wolff H, Landthaler M, editors. Braun-Falcos dermatol. 3rd ed. Heidelberg: Springer; 2009. p. 456\u201372.","edition":"3"},{"key":"318_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","volume":"113","author":"SGO Johansson","year":"2004","unstructured":"Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the nomenclature review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832\u20136.","journal-title":"J Allergy Clin Immunol."},{"key":"318_CR8","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","volume":"333","author":"JC Roujeau","year":"1995","unstructured":"Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600\u20137.","journal-title":"N Engl J Med"},{"key":"318_CR9","doi-asserted-by":"publisher","first-page":"e78490","DOI":"10.1371\/journal.pone.0078490","volume":"8","author":"CV Borlongan","year":"2013","unstructured":"Borlongan CV, Burns J, Tajiri N, Stahl CE, Weinbren NL, Shojo H, et al. Epidemiological survey-based formulae to approximate incidence and prevalence of neurological disorders in the United States: a meta-analysis. PloS One. 2013;8:e78490.","journal-title":"PloS One."},{"key":"318_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","volume":"68","author":"D Hirtz","year":"2007","unstructured":"Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the \u201ccommon\u201d neurologic disorders? Neurology. 2007;68:326\u201337.","journal-title":"Neurology."},{"key":"318_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1590\/abd1806-4841.20153334","volume":"90","author":"MJ Tarazona","year":"2015","unstructured":"Tarazona MJ, Mota AN, Gripp AC, Unterstell N, Bressan AL. Bullous pemphigoid and neurological disease: statistics from a dermatology service. An Bras Dermatol. 2015;90:280\u20132.","journal-title":"An Bras Dermatol"},{"key":"318_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","volume":"165","author":"YJ Chen","year":"2011","unstructured":"Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011;165:593\u20139.","journal-title":"Br J Dermatol"},{"key":"318_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/jid.2010.357","volume":"131","author":"SM Langan","year":"2011","unstructured":"Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011;131:631\u20136.","journal-title":"J Invest Dermatol"},{"key":"318_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/archderm.136.4.521","volume":"136","author":"O Chosidow","year":"2000","unstructured":"Chosidow O, Doppler V, Bensimon G, Joly P, Salachas F, Lacomblez L, et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease? Arch Dermatol. 2000;136:521\u20134.","journal-title":"Arch Dermatol."},{"key":"318_CR15","doi-asserted-by":"publisher","unstructured":"Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2006;(1):CD001190. doi:10.1002\/14651858.CD001190.pub2.","DOI":"10.1002\/14651858.CD001190.pub2"},{"key":"318_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/bmj.317.7161.787","volume":"19","author":"CA Bryant","year":"1998","unstructured":"Bryant CA, Ouldred E, Jackson SHD, Kinirons MT. Purpuric rash with donepezil treatment. Br Med J. 1998;19:787.","journal-title":"Br Med J"},{"key":"318_CR17","doi-asserted-by":"crossref","unstructured":"Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer\u2019s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dement Basel Switz. 1996;7:293\u2013303.","DOI":"10.1159\/000106895"},{"key":"318_CR18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/gps.2387","volume":"25","author":"RW Jones","year":"2010","unstructured":"Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry. 2010;25:547\u201353.","journal-title":"Int J Geriatr Psychiatry"},{"key":"318_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1517\/14740330903439717","volume":"9","author":"T Darreh-Shori","year":"2010","unstructured":"Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer\u2019s disease and Parkinson\u2019s disease dementia. Expert Opin Drug Saf. 2010;9:167\u201376.","journal-title":"Expert Opin Drug Saf"},{"key":"318_CR20","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1111\/jgs.13045","volume":"62","author":"NMS Gol\u00fcke","year":"2014","unstructured":"Gol\u00fcke NMS, van Strien AM, Dautzenberg PJL, Jessurun N, Keijsers CJPW. Skin lesions after oral acetylcholinesterase inhibitor therapy: a case report. J Am Geriatr Soc. 2014;62:2012\u20133.","journal-title":"J Am Geriatr Soc"},{"key":"318_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1398-9995.2009.02258.x","volume":"65","author":"M Makris","year":"2010","unstructured":"Makris M, Koulouris S, Koti I, Aggelides X, Kalogeromitros D. Maculopapular eruption to rivastigmine\u2019s transdermal patch application and successful oral desensitization. Allergy. 2010;65:925\u20136.","journal-title":"Allergy."},{"key":"318_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/752098","volume":"2011","author":"T Grieco","year":"2011","unstructured":"Grieco T, Rossi M, Faina V, De Marco I, Pigatto P, Calvieri S. An atypical cutaneous reaction to rivastigmine transdermal patch. J Allergy. 2011;2011:1\u20132.","journal-title":"J Allergy"},{"key":"318_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2165\/11318350-000000000-00000","volume":"12","author":"G Allain-Veyrac","year":"2011","unstructured":"Allain-Veyrac G, Lebreton A, Collonnier C, Jolliet P. First case of symmetric drug-related intertriginous and flexural exanthema (sdrife) due to rivastigmine? Am J Clin Dermatol. 2011;12:210\u20133.","journal-title":"Am J Clin Dermatol."},{"key":"318_CR24","doi-asserted-by":"publisher","unstructured":"McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154. doi:10.1002\/14651858.CD003154.pub5.","DOI":"10.1002\/14651858.CD003154.pub5"},{"key":"318_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","volume":"27","author":"GT Grossberg","year":"2013","unstructured":"Grossberg GT, Manes F, Allegri RF, Guti\u00e9rrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28\u00a0mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe alzheimer\u2019s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27:469\u201378.","journal-title":"CNS Drugs."},{"key":"318_CR26","doi-asserted-by":"publisher","unstructured":"Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447. doi:10.1002\/14651858.CD001447.pub3.","DOI":"10.1002\/14651858.CD001447.pub3"},{"key":"318_CR27","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1212\/01.wnl.0000249182.09143.20","volume":"67","author":"EJ Sorenson","year":"2006","unstructured":"Sorenson EJ. An acute, life-threatening, hypersensitivity reaction to riluzole. Neurology. 2006;67:2260\u20131.","journal-title":"Neurology."},{"key":"318_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.pharep.2014.11.009","volume":"67","author":"B B\u0142aszczyk","year":"2015","unstructured":"B\u0142aszczyk B, Laso\u0144 W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep. 2015;67:426\u201334.","journal-title":"Pharmacol Rep"},{"key":"318_CR29","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1212\/01.wnl.0000261917.83337.db","volume":"68","author":"H Arif","year":"2007","unstructured":"Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68:1701\u20139.","journal-title":"Neurology."},{"key":"318_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S1734-1140(13)71015-6","volume":"65","author":"B B\u0142aszczyk","year":"2013","unstructured":"B\u0142aszczyk B, Szpringer M, Czuczwar SJ, Laso\u0144 W. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. Pharmacol Rep PR. 2013;65:399\u2013409.","journal-title":"Pharmacol Rep PR."},{"key":"318_CR31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/j.1528-1167.2007.01109.x","volume":"48","author":"S Alvestad","year":"2007","unstructured":"Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48:1360\u20135.","journal-title":"Epilepsia."},{"key":"318_CR32","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","volume":"11","author":"P Perucca","year":"2012","unstructured":"Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792\u2013802.","journal-title":"Lancet Neurol."},{"key":"318_CR33","first-page":"1330","volume-title":"Fitzpatrick\u2019s dermatology in general medicine","author":"N Shear","year":"2003","unstructured":"Shear N, Knowles S, Sullivan J. Cutaneous reactions to drugs. In: Freedburg I, Eisen A, Wolff K, editors. Fitzpatrick\u2019s dermatology in general medicine. 6th ed. New York: McGraw-Hill; 2003. p. 1330-7.","edition":"6"},{"key":"318_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.tox.2004.12.023","volume":"209","author":"N Yawalkar","year":"2005","unstructured":"Yawalkar N. Drug-induced exanthems. Toxicology. 2005;209:131\u20134.","journal-title":"Toxicology."},{"key":"318_CR35","doi-asserted-by":"crossref","unstructured":"McKenna JK, Leiferman KM. Dermatologic drug reactions. Immunol Allergy Clin North Am. 2004;24:399\u2013423 (vi).","DOI":"10.1016\/j.iac.2004.03.007"},{"key":"318_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","volume":"126","author":"HL Chan","year":"1990","unstructured":"Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43\u20137.","journal-title":"Arch Dermatol"},{"key":"318_CR37","doi-asserted-by":"crossref","unstructured":"Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2009;7:142\u201360 (quiz 161\u20132).","DOI":"10.1111\/j.1610-0387.2008.06878.x"},{"key":"318_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/0022-3859.81865","volume":"57","author":"M Barvaliya","year":"2011","unstructured":"Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens\u2013Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med. 2011;57:115\u20139.","journal-title":"J Postgrad Med"},{"key":"318_CR39","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2165\/00002018-200730110-00003","volume":"30","author":"L Valeyrie-Allanore","year":"2007","unstructured":"Valeyrie-Allanore L, Sassolas B, Roujeau J-C. Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30:1011\u201330.","journal-title":"Drug Saf."},{"key":"318_CR40","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1212\/WNL.0b013e31823b478c","volume":"77","author":"C-Y Yang","year":"2011","unstructured":"Yang C-Y, Dao R-L, Lee T-J, Lu C-W, Yang C-H, Hung S-I, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology. 2011;77:2025\u201333.","journal-title":"Neurology."},{"key":"318_CR41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ophtha.2004.11.035","volume":"112","author":"MA Di Pascuale","year":"2005","unstructured":"Di Pascuale MA, Espana EM, Liu DT-S, Kawakita T, Li W, Gao YY, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 2005;112:904\u201312.","journal-title":"Ophthalmology."},{"key":"318_CR42","first-page":"15","volume":"42","author":"VK Sharma","year":"1996","unstructured":"Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: an overview. J Postgrad Med. 1996;42:15\u201322.","journal-title":"J Postgrad Med"},{"key":"318_CR43","doi-asserted-by":"crossref","unstructured":"Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.e1\u201314 (quiz 706\u20138).","DOI":"10.1016\/j.jaad.2013.01.033"},{"key":"318_CR44","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071\u201380.","journal-title":"Br J Dermatol"},{"issue":"Suppl 7","key":"318_CR45","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1528-1157.1998.tb01678.x","volume":"39","author":"RG Schlienger","year":"1998","unstructured":"Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia. 1998;39(Suppl 7):S3\u20137.","journal-title":"Epilepsia."},{"key":"318_CR46","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1345\/aph.18422","volume":"33","author":"IC Wong","year":"1999","unstructured":"Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 1999;33:1037\u201342.","journal-title":"Ann Pharmacother"},{"key":"318_CR47","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1345\/aph.1P350","volume":"44","author":"G Roquin","year":"2010","unstructured":"Roquin G, Peres M, Lerolle N, Dib N, Mercat A, Croue A, et al. First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis. Ann Pharmacother. 2010;44:1998\u20132000.","journal-title":"Ann Pharmacother"},{"issue":"Suppl 14","key":"318_CR48","first-page":"22","volume":"62","author":"AA Hebert","year":"2001","unstructured":"Hebert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry. 2001;62(Suppl 14):22\u20136.","journal-title":"J Clin Psychiatry"},{"key":"318_CR49","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/WNL.53.6.1170","volume":"53","author":"S Arroyo","year":"1999","unstructured":"Arroyo S, Sander JW. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Neurology. 1999;53:1170\u20134.","journal-title":"Neurology."},{"key":"318_CR50","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/j.1365-2133.1996.tb07953.x","volume":"134","author":"S Chopra","year":"1996","unstructured":"Chopra S, Levell NJ, Cowley G, Gilkes JJ. Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Br J Dermatol. 1996;134:1109\u201312.","journal-title":"Br J Dermatol"},{"key":"318_CR51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5005\/jcdp-8-6-50","volume":"8","author":"A Lafzi","year":"2007","unstructured":"Lafzi A, Farahani RMZ, Shoja MAM. Phenobarbital-induced gingival hyperplasia. J Contemp Dent Pract. 2007;8:50\u20136.","journal-title":"J Contemp Dent Pract"},{"key":"318_CR52","volume-title":"Antiepileptic drugs","author":"R Levy","year":"2002","unstructured":"Levy R, Mattson R, Meldrum B, Perucca E. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.","edition":"5"},{"key":"318_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000105","author":"RT Jones","year":"2014","unstructured":"Jones RT, Evans W, Mersfelder TL, Kavanaugh K. Rare red rashes: a case report of levetiracetam-induced cutaneous reaction and review of the literature. Am J Ther. 2014. doi:10.1097\/MJT.0000000000000105.","journal-title":"Am J Ther."},{"key":"318_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/2013.jamadermatol.266","volume":"149","author":"TA Duong","year":"2013","unstructured":"Duong TA, Haddad C, Valeyrie-Allanore L, Sbidian E, Chosidow O, Wolkenstein P. Levetiracetam: a possible new inducer of toxic epidermal necrolysis and Stevens\u2013Johnson syndrome in 2 cases. JAMA Dermatol. 2013;149:113\u20135.","journal-title":"JAMA Dermatol."},{"key":"318_CR55","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.seizure.2012.09.005","volume":"21","author":"L-P Zou","year":"2012","unstructured":"Zou L-P, Ding C-H, Song Z-J, Li X-F. Stevens\u2013Johnson syndrome induced by levetiracetam. Seizure. 2012;21:823\u20135.","journal-title":"Seizure."},{"key":"318_CR56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D39346H1K6","volume":"19","author":"Y Yesilova","year":"2013","unstructured":"Yesilova Y, Turan E, Sonmez A, Ozardali I. A case of erythema multiforme developing after levetiracetam therapy. Dermatol Online J. 2013;19:12.","journal-title":"Dermatol Online J."},{"key":"318_CR57","first-page":"409","volume":"9","author":"TC Beswick","year":"2010","unstructured":"Beswick TC, Cohen JB. Dose-related levetiracetam-induced reticulated drug eruption. J Drugs Dermatol JDD. 2010;9:409\u201310.","journal-title":"J Drugs Dermatol JDD."},{"key":"318_CR58","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1345\/aph.1R084","volume":"46","author":"S G\u00f3mez-Zorrilla","year":"2012","unstructured":"G\u00f3mez-Zorrilla S, Ferraz AV, Pedr\u00f3s C, Lemus M, Pe\u00f1a C. Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome. Ann Pharmacother. 2012;46:e20.","journal-title":"Ann Pharmacother"},{"key":"318_CR59","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.pediatrneurol.2005.10.004","volume":"34","author":"C Cerminara","year":"2006","unstructured":"Cerminara C, Seri S, Bombardieri R, Pinci M, Curatolo P. Hypohidrosis during topiramate treatment: a rare and reversible side effect. Pediatr Neurol. 2006;34:392\u20134.","journal-title":"Pediatr Neurol"},{"key":"318_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ppul.21563","volume":"47","author":"L Guglani","year":"2012","unstructured":"Guglani L, Sitwat B, Lower D, Kurland G, Weiner DJ. Elevated sweat chloride concentration in children without cystic fibrosis who are receiving topiramate therapy. Pediatr Pulmonol. 2012;47:429\u201333.","journal-title":"Pediatr Pulmonol"},{"key":"318_CR61","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2340\/00015555-0696","volume":"89","author":"E Castela","year":"2009","unstructured":"Castela E, Thomas P, Bronsard V, Lacour J-P, Ortonne J-P, Passeron T. Blue pseudochromhidrosis secondary to topiramate treatment. Acta Derm Venereol. 2009;89:538\u20139.","journal-title":"Acta Derm Venereol"},{"key":"318_CR62","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4103\/0019-5154.84746","volume":"56","author":"A Aggarwal","year":"2011","unstructured":"Aggarwal A, Kumar R, Sharma RC, Sharma DD. Topiramate induced pruritus in a patient with alcohol dependence. Indian J Dermatol. 2011;56:421\u20132.","journal-title":"Indian J Dermatol"},{"key":"318_CR63","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1059-1311(03)00051-7","volume":"12","author":"JG Ochoa","year":"2003","unstructured":"Ochoa JG. Pruritus, a rare but troublesome adverse reaction of topiramate. Seizure. 2003;12:516\u20138.","journal-title":"Seizure."},{"key":"318_CR64","first-page":"321","volume":"3","author":"N Scheinfeld","year":"2004","unstructured":"Scheinfeld N, Spahn C. Palmar erythema due to topiramate. J Drugs Dermatol JDD. 2004;3:321\u20132.","journal-title":"J Drugs Dermatol JDD."},{"key":"318_CR65","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1468-3083.2008.02988.x","volume":"23","author":"Y-C Chen","year":"2009","unstructured":"Chen Y-C, Chu C-Y, Hsiao C-H. Oxcarbazepine-induced Stevens\u2013Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol Venereol JEADV. 2009;23:702\u20133.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"318_CR66","first-page":"853281","volume":"2014","author":"SL Cornell","year":"2014","unstructured":"Cornell SL, DiBlasi D, Arora NS. drug reaction with eosinophilia and systemic symptoms: DRESS following initiation of oxcarbazepine with elevated human herpesvirus-6 titer. Case Rep Dermatol Med. 2014;2014:853281.","journal-title":"Case Rep Dermatol Med"},{"key":"318_CR67","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.seizure.2012.06.014","volume":"21","author":"N He","year":"2012","unstructured":"He N, Min F-L, Shi Y-W, Guo J, Liu X-R, Li B-M, et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. Seizure. 2012;21:614\u20138.","journal-title":"Seizure."},{"key":"318_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4103\/0976-500X.142456","volume":"5","author":"A Massot","year":"2014","unstructured":"Massot A, Gimenez-Arnau A. Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine. J Pharmacol Pharmacother. 2014;5:271\u20134.","journal-title":"J Pharmacol Pharmacother"},{"key":"318_CR69","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/epi.12749","volume":"55","author":"M Baulac","year":"2014","unstructured":"Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study. Epilepsia. 2014;55:1534\u201343.","journal-title":"Epilepsia."},{"key":"318_CR70","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0887-8994(00)00144-2","volume":"23","author":"A Okumura","year":"2000","unstructured":"Okumura A, Ishihara N, Kato T, Hayakawa F, Kuno K, Watanabe K. Predictive value of acetylcholine stimulation testing for oligohidrosis caused by zonisamide. Pediatr Neurol. 2000;23:59\u201361.","journal-title":"Pediatr Neurol"},{"key":"318_CR71","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S0887-8994(02)00511-8","volume":"28","author":"JF Knudsen","year":"2003","unstructured":"Knudsen JF, Thambi LR, Kapcala LP, Racoosin JA. Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol. 2003;28:184\u20139.","journal-title":"Pediatr Neurol"},{"key":"318_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eplepsyres.2004.06.009","volume":"62","author":"PA Low","year":"2004","unstructured":"Low PA, James S, Peschel T, Leong R, Rothstein A. Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res. 2004;62:27\u201334.","journal-title":"Epilepsy Res."},{"key":"318_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4103\/0378-6323.39714","volume":"74","author":"F Kaliyadan","year":"2008","unstructured":"Kaliyadan F, Manoj J, Venkitakrishnan S. Xerosis and pityriasis alba-like changes associated with zonisamide. Indian J Dermatol Venereol Leprol. 2008;74:165\u20136.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"318_CR74","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2340\/00015555-1863","volume":"95","author":"R Shibuya","year":"2015","unstructured":"Shibuya R, Tanizaki H, Nakajima S, Koyanagi I, Kataoka TR, Miyachi Y, et al. DIHS\/DRESS with remarkable eosinophilic pneumonia caused by zonisamide. Acta Derm Venereol. 2015;95:229\u201330.","journal-title":"Acta Derm Venereol"},{"key":"318_CR75","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1468-3083.2012.04547.x","volume":"27","author":"H Uhara","year":"2013","unstructured":"Uhara H, Saiki M, Kawachi S, Ashida A, Oguchi S, Okuyama R. Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids. J Eur Acad Dermatol Venereol JEADV. 2013;27:722\u20136.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"318_CR76","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/j.1365-2133.2007.08167.x","volume":"157","author":"M Tohyama","year":"2007","unstructured":"Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007;157:934\u201340.","journal-title":"Br J Dermatol"},{"key":"318_CR77","first-page":"918","volume":"38","author":"T Murata","year":"2011","unstructured":"Murata T, Endo Y, Katoh M, Miyachi Y, Kabashima K. Case of drug rash with eosinophilia and systemic symptoms induced by zonisamide and reactivation of human herpes virus 7. J Dermatol. 2011;38:918\u201320.","journal-title":"J Dermatol"},{"key":"318_CR78","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2169\/internalmedicine.49.2451","volume":"49","author":"Y Fujita","year":"2010","unstructured":"Fujita Y, Hasegawa M, Nabeshima K, Tomita M, Murakami K, Nakai S, et al. Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. Intern Med Tokyo Jpn. 2010;49:409\u201313.","journal-title":"Intern Med Tokyo Jpn"},{"key":"318_CR79","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1600-0625.2008.00748.x","volume":"17","author":"MG Neuman","year":"2008","unstructured":"Neuman MG, Shear NH, Malkiewicz IM, Kessas M, Lee AW, Cohen L. Predicting possible zonisamide hypersensitivity syndrome. Exp Dermatol. 2008;17:1045\u201351.","journal-title":"Exp Dermatol"},{"key":"318_CR80","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/archdermatol.2007.48","volume":"144","author":"Y Teraki","year":"2008","unstructured":"Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol. 2008;144:232\u20135.","journal-title":"Arch Dermatol"},{"key":"318_CR81","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2217\/pgs.13.180","volume":"14","author":"N Kaniwa","year":"2013","unstructured":"Kaniwa N, Sugiyama E, Saito Y, Kurose K, Maekawa K, Hasegawa R, et al. Specific HLA types are associated with antiepileptic drug-induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. 2013;14:1821\u201331.","journal-title":"Pharmacogenomics."},{"key":"318_CR82","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","volume":"52","author":"V Biton","year":"2015","unstructured":"Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav EB. 2015;52:119\u201327.","journal-title":"Epilepsy Behav EB."},{"key":"318_CR83","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1684\/epd.2014.0667","volume":"16","author":"MZ Koubeissi","year":"2014","unstructured":"Koubeissi MZ, Vismer M, Ehrlich A. Lacosamide-induced rash. Epileptic Disord Int Epilepsy J Videotape. 2014;16:380\u20133.","journal-title":"Epileptic Disord Int Epilepsy J Videotape"},{"key":"318_CR84","first-page":"121","volume":"27","author":"AK Yapici","year":"2014","unstructured":"Yapici AK, Fidanci MK, Kilic S, Balamtekin N, Mutluay Arslan M, Yavuz ST, et al. Stevens\u2013Johnson Syndrome triggered by a combination of clobazam, lamotrigine and valproic acid in a 7-year-old child. Ann Burns Fire Disasters. 2014;27:121\u20135.","journal-title":"Ann Burns Fire Disasters"},{"key":"318_CR85","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1111\/pde.12527","volume":"32","author":"CD Dang","year":"2015","unstructured":"Dang CD, Beets-Shay L, Kahn EC. Toxic epidermal necrolysis triggered by clobazam: a case report in a 13-year-old girl. Pediatr Dermatol. 2015;32:e102\u20133.","journal-title":"Pediatr Dermatol"},{"key":"318_CR86","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1046\/j.1365-2133.1996.d01-1111.x","volume":"135","author":"P Redondo","year":"1996","unstructured":"Redondo P, Vicente J, Espa\u00f1a A, Subira ML, De Felipe I, Quintanilla E. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol. 1996;135:999\u20131002.","journal-title":"Br J Dermatol"},{"key":"318_CR87","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1046\/j.1365-2230.2000.00619.x","volume":"25","author":"JF Setterfield","year":"2000","unstructured":"Setterfield JF, Robinson R, MacDonald D, Calonje E. Coma-induced bullae and sweat gland necrosis following clobazam. Clinical dermatology. Concise report. Clin Exp Dermatol. 2000;25:215\u20138.","journal-title":"Clin Exp Dermatol"},{"key":"318_CR88","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1046\/j.1365-2230.1998.00358.x","volume":"23","author":"B Amichai","year":"1998","unstructured":"Amichai B, Grunwald MH. Erythema multiforme due to clonazepam\u2014supportive evidence from the macrophage migration inhibition factor test. Clin Exp Dermatol. 1998;23:206\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"318_CR89","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1177\/0091270011423923","volume":"52","author":"M-C Lee","year":"2012","unstructured":"Lee M-C, Su C-P, Wang C-H, Lan C-C, Wu T-W. Suspected clonazepam-induced bullous dermatosis in a patient with respiratory failure. J Clin Pharmacol. 2012;52:1607\u20139.","journal-title":"J Clin Pharmacol"},{"key":"318_CR90","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0190-9622(96)80143-5","volume":"34","author":"KB Gordon","year":"1996","unstructured":"Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, et al. Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996;34:304\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"318_CR91","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1089\/cap.2011.0059","volume":"22","author":"RN Munoli","year":"2012","unstructured":"Munoli RN, Praharaj SK, Bhatt SM. Localized exfoliating rash with paresthesia possibly due to clonazepam. J Child Adolesc Psychopharmacol. 2012;22:320\u20131.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"318_CR92","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0920-1211(00)00149-2","volume":"41","author":"D Schmidt","year":"2000","unstructured":"Schmidt D, Gram L, Brodie M, Kr\u00e4mer G, Perucca E, K\u00e4lvi\u00e4inen R, et al. Tiagabine in the treatment of epilepsy\u2014a clinical review with a guide for the prescribing physician. Epilepsy Res. 2000;41:245\u201351.","journal-title":"Epilepsy Res."},{"key":"318_CR93","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/NDT.S833","volume":"4","author":"J Bauer","year":"2008","unstructured":"Bauer J, Cooper-Mahkorn D. Tiagabine: efficacy and safety in partial seizures\u2014current status. Neuropsychiatr Dis Treat. 2008;4:731\u20136.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"318_CR94","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2165\/00003495-199855030-00013","volume":"55","author":"JC Adkins","year":"1998","unstructured":"Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs. 1998;55:437\u201360.","journal-title":"Drugs."},{"key":"318_CR95","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-006-0236-6","volume":"63","author":"ML Iorio","year":"2007","unstructured":"Iorio ML, Moretti U, Colcera S, Magro L, Meneghelli I, Motola D, et al. Use and safety profile of antiepileptic drugs in Italy. Eur J Clin Pharmacol. 2007;63:409\u201315.","journal-title":"Eur J Clin Pharmacol"},{"key":"318_CR96","doi-asserted-by":"crossref","unstructured":"Xiao Y, Gan L, Wang J, Luo M, Luo H. Vigabatrin versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2015;11:CD008781.","DOI":"10.1002\/14651858.CD008781.pub3"},{"key":"318_CR97","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/archneur.1995.00540340081016","volume":"52","author":"R K\u00e4lvi\u00e4inen","year":"1995","unstructured":"K\u00e4lvi\u00e4inen R, Aiki\u00e4 M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol. 1995;52:989\u201396.","journal-title":"Arch Neurol"},{"key":"318_CR98","doi-asserted-by":"crossref","unstructured":"Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet Lond Engl. 1999;354:13\u20139.","DOI":"10.1016\/S0140-6736(98)10531-7"},{"key":"318_CR99","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","volume":"52","author":"G Zaccara","year":"2011","unstructured":"Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826\u201336.","journal-title":"Epilepsia."},{"key":"318_CR100","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1345\/aph.1L305","volume":"42","author":"TL Smith","year":"2008","unstructured":"Smith TL, Baldwin A, Cunningham LL, Cook AM. Rash associated with pregabalin use. Ann Pharmacother. 2008;42:1899\u2013902.","journal-title":"Ann Pharmacother"},{"key":"318_CR101","doi-asserted-by":"publisher","first-page":"522","DOI":"10.4103\/0253-7613.117748","volume":"45","author":"A Bamanikar","year":"2013","unstructured":"Bamanikar A, Dhobale S, Lokwani S. Pregabalin hypersensitivity in a patient treated for postherpetic neuralgia. Indian J Pharmacol. 2013;45:522\u20133.","journal-title":"Indian J Pharmacol"},{"key":"318_CR102","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1046\/j.1528-1157.2002.01702.x","volume":"43","author":"LV Wilton","year":"2002","unstructured":"Wilton LV, Shakir S. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia. 2002;43:983\u201392.","journal-title":"Epilepsia."},{"key":"318_CR103","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/SMJ.0b013e3181e1e449","volume":"103","author":"PR Lopez","year":"2010","unstructured":"Lopez PR, Rachael T, Leicht S, Smalligan RD. Gabapentin-induced delusions of parasitosis. South Med J. 2010;103:711\u20132.","journal-title":"South Med J"},{"key":"318_CR104","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.1L354","volume":"43","author":"VMGJ Gijsen","year":"2009","unstructured":"Gijsen VMGJ, de Wildt SN, Ito S. Probability of rash related to gabapentin therapy in a child. Ann Pharmacother. 2009;43:387\u20139.","journal-title":"Ann Pharmacother"},{"key":"318_CR105","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00002826-200103000-00007","volume":"24","author":"MV Ragucci","year":"2001","unstructured":"Ragucci MV, Cohen JM. Gabapentin-induced hypersensitivity syndrome. Clin Neuropharmacol. 2001;24:103\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"318_CR106","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/WNF.0b013e31806ad6cb","volume":"31","author":"S Sahin","year":"2008","unstructured":"Sahin S, Comert A, Akin O, Ayalp S, Karsidag S. Cutaneous drug eruptions by current antiepileptics: case reports and alternative treatment options. Clin Neuropharmacol. 2008;31:93\u20136.","journal-title":"Clin Neuropharmacol"},{"key":"318_CR107","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/153473460400300304","volume":"3","author":"U Wollina","year":"2004","unstructured":"Wollina U, Koch A, Kr\u00f6nert C, K\u00f6stler E. Gabapentin-induced generalized cutaneous small-vessel leukocytoclastic vasculitis. Int J Low Extrem Wounds. 2004;3:123\u20134.","journal-title":"Int J Low Extrem Wounds"},{"key":"318_CR108","first-page":"42","volume":"44","author":"DYH Poon","year":"2003","unstructured":"Poon DYH, Law NM. A case of cutaneous leukocytoclastic vasculitis associated with gabapentin. Singap Med J. 2003;44:42\u20134.","journal-title":"Singap Med J."},{"key":"318_CR109","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007691-199902000-00022","volume":"21","author":"JC DeToledo","year":"1999","unstructured":"DeToledo JC, Minagar A, Lowe MR, Ramsay RE. Skin eruption with gabapentin in a patient with repeated AED-induced Stevens\u2013Johnson\u2019s syndrome. Ther Drug Monit. 1999;21:137\u20138.","journal-title":"Ther Drug Monit"},{"key":"318_CR110","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2147\/PPA.S63951","volume":"9","author":"A Schulze-Bonhage","year":"2015","unstructured":"Schulze-Bonhage A, Hintz M. Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2015;9:1143\u201351.","journal-title":"Patient Prefer Adherence"},{"key":"318_CR111","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1212\/WNL.0000000000001052","volume":"83","author":"K Shimabukuro","year":"2014","unstructured":"Shimabukuro K, Gibbon F, Kerstetter J, Tinsley C, Ashwal S. DRESS associated with perampanel administration in a child with drug-resistant epilepsy. Neurology. 2014;83:2188.","journal-title":"Neurology."},{"key":"318_CR112","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2042098614560736","volume":"6","author":"S Clark","year":"2015","unstructured":"Clark S, Antell A, Kaufman K. New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf. 2015;6:15\u20139.","journal-title":"Ther Adv Drug Saf"},{"key":"318_CR113","doi-asserted-by":"crossref","unstructured":"Garin Shkolnik T, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L, et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol. 2014;150:984\u20139.","DOI":"10.1001\/jamadermatol.2013.8895"},{"key":"318_CR114","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D37DN5M9VT","volume":"19","author":"S Shahbaz","year":"2013","unstructured":"Shahbaz S, Sivamani RK, Konia T, Burrall B. A case of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) related to rufinamide. Dermatol Online J. 2013;19:4.","journal-title":"Dermatol Online J"},{"key":"318_CR115","doi-asserted-by":"crossref","unstructured":"Chambel M, Mascarenhas MI, Regala J, Gouveia C, Prates S. Clinical Stevens\u2013Johnson syndrome and rufinamide: a clinical case. Allergol Immunopathol (Madr). 2013;41:68\u20139.","DOI":"10.1016\/j.aller.2011.12.004"},{"key":"318_CR116","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.braindev.2014.12.010","volume":"37","author":"M Ide","year":"2015","unstructured":"Ide M, Kato T, Nakata M, Saito K, Yoshida T, Awaya T, et al. A granulocytosis associated with rufinamide: a case report. Brain Dev. 2015;37:825\u20138.","journal-title":"Brain Dev."},{"key":"318_CR117","doi-asserted-by":"publisher","unstructured":"Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with huntington\u2019s and other diseases. Tremor Hyperkinetic Mov. 2013;3. doi:10.7916\/D8BK1B2D.","DOI":"10.7916\/D8BK1B2D"},{"key":"318_CR118","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","volume":"31","author":"A Fasano","year":"2008","unstructured":"Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol. 2008;31:313\u20138.","journal-title":"Clin Neuropharmacol"},{"key":"318_CR119","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/jnnp.2003.031286","volume":"75","author":"J Olesen","year":"2004","unstructured":"Olesen J, Steiner TJ. The International classification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry. 2004;75:808\u201311.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"318_CR120","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"MJ Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3\u201320.","journal-title":"Headache."},{"key":"318_CR121","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1046\/j.1526-4610.2001.041007638.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638\u201345.","journal-title":"Headache."},{"key":"318_CR122","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s11095-007-9317-1","volume":"24","author":"SJ Siegel","year":"2007","unstructured":"Siegel SJ, O\u2019Neill C, Dub\u00e9 LM, Kaldeway P, Morris R, Jackson D, et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res. 2007;24:1919\u201326.","journal-title":"Pharm Res"},{"key":"318_CR123","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1526-4610.2012.02198.x","volume":"52","author":"J Goldstein","year":"2012","unstructured":"Goldstein J, Smith TR, Pugach N, Griesser J, Sebree T, Pierce M. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012;52:1402\u201310.","journal-title":"Headache."},{"key":"318_CR124","unstructured":"Merck Sharp & Dohme Corp. A randomized, placebo-controlled, parallel-groups, outpatient study to examine the safety, tolerability, and efficacy of single oral doses of MK0462 5\u00a0mg, MK0462 10\u00a0mg, and Sumatriptan 100\u00a0mg for acute treatment of migraine. In: ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine (US); Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00898677. Accessed 20 Aug 2015."},{"key":"318_CR125","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2165\/11209380-000000000-00000","volume":"26","author":"M Sanford","year":"2012","unstructured":"Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs. 2012;26:791\u2013811.","journal-title":"CNS Drugs."},{"key":"318_CR126","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40263-013-0061-2","volume":"27","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013;27:385\u201394.","journal-title":"CNS Drugs."},{"key":"318_CR127","volume-title":"A retrospective study of cutaneous drug reactions in an outpatient population","author":"F Drago","year":"2015","unstructured":"Drago F, Cogorno L, Agnoletti AF, Ciccarese G, Parodi A. A retrospective study of cutaneous drug reactions in an outpatient population. Pharm: Int. J. Clin; 2015."},{"key":"318_CR128","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1590\/abd1806-4841.20142997","volume":"89","author":"LR Grando","year":"2014","unstructured":"Grando LR, Schmitt TAB, Bakos RM. Severe cutaneous reactions to drugs in the setting of a general hospital. An Bras Dermatol. 2014;89:758\u201362.","journal-title":"An Bras Dermatol"},{"key":"318_CR129","doi-asserted-by":"crossref","unstructured":"Ward KE, Archambault R, Mersfelder TL. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: a review of the literature. Am J Health Syst Pharm. 2010;67:206\u201313.","DOI":"10.2146\/ajhp080603"},{"key":"318_CR130","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40263-014-0202-2","volume":"28","author":"FG Freitag","year":"2014","unstructured":"Freitag FG, Shumate D. Current and investigational drugs for the prevention of migraine in adults and children. CNS Drugs. 2014;28:921\u20137.","journal-title":"CNS Drugs."},{"key":"318_CR131","first-page":"95","volume":"24","author":"S Halevy","year":"1979","unstructured":"Halevy S, Feuerman EJ. Psoriasiform eruption induced by propranolol. Cutis. 1979;24:95\u20138.","journal-title":"Cutis."},{"key":"318_CR132","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.0954-6820.1976.tb06749.x","volume":"199","author":"HA Jensen","year":"1976","unstructured":"Jensen HA, Mikkelsen HI, Wadskov S, Sondergaard J. Cutaneous reactions to propranolol (Inderal). Acta Med Scand. 1976;199:363\u20137.","journal-title":"Acta Med Scand"},{"key":"318_CR133","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000250296","volume":"162","author":"HA Neumann","year":"1981","unstructured":"Neumann HA, van Joost T. Adverse reactions of the skin to metoprolol and other beta-adrenoreceptor-blocking agents. Dermatologica. 1981;162:330\u20135.","journal-title":"Dermatologica."},{"key":"318_CR134","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2340\/0001555556239243","volume":"56","author":"J Sondergaard","year":"1976","unstructured":"Sondergaard J, Wadskov S, Jensen HA, Mikkelsen HI. Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin). Acta Derm Venereol. 1976;56:239\u201343.","journal-title":"Acta Derm Venereol"},{"key":"318_CR135","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-4362.1988.tb02419.x","volume":"27","author":"MC Heng","year":"1988","unstructured":"Heng MC, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption. Clinical and pathogenetic aspects. Int J Dermatol. 1988;27:619\u201327.","journal-title":"Int J Dermatol"},{"key":"318_CR136","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/BF00371785","volume":"283","author":"S Halevy","year":"1991","unstructured":"Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol\u2014the role of an immunological mechanism. Arch Dermatol Res. 1991;283:472\u20133.","journal-title":"Arch Dermatol Res."},{"key":"318_CR137","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0190-9622(88)70242-X","volume":"19","author":"MH Gold","year":"1988","unstructured":"Gold MH, Holy AK, Roenigk HH. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol. 1988;19:837\u201341.","journal-title":"J Am Acad Dermatol"},{"key":"318_CR138","first-page":"153","volume":"94","author":"CW Stanford","year":"2014","unstructured":"Stanford CW, Kollipara R, Melookaran AM, Hall JC. Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate. Cutis. 2014;94:153\u20135.","journal-title":"Cutis."},{"key":"318_CR139","first-page":"746","volume":"4","author":"A Perry","year":"2005","unstructured":"Perry A, Sparling JD, Pennington M. Bullous pemphigoid following therapy with an oral beta-blocker. J Drugs Dermatol JDD. 2005;4:746\u20138.","journal-title":"J Drugs Dermatol JDD"},{"key":"318_CR140","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0002-9378(84)80011-3","volume":"150","author":"AH Stage","year":"1984","unstructured":"Stage AH, Humeniuk JM, Easley WK. Bullous pemphigoid of the vulva: a case report. Am J Obstet Gynecol. 1984;150:169\u201370.","journal-title":"Am J Obstet Gynecol"},{"key":"318_CR141","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1046\/j.1526-4610.1999.3910758.x","volume":"39","author":"ZH Bajwa","year":"1999","unstructured":"Bajwa ZH, Sami N, Flory C. Severe acne as a side effect of propranolol and nadolol in a migraineur. Headache. 1999;39:758\u201360.","journal-title":"Headache."},{"key":"318_CR142","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3390\/toxins7072659","volume":"7","author":"D Szok","year":"2015","unstructured":"Szok D, Cs\u00e1ti A, V\u00e9csei L, Tajti J. Treatment of chronic migraine with onabotulinumtoxinA: mode of action. Efficacy and safety. Toxins. 2015;7:2659\u201373.","journal-title":"Toxins."},{"issue":"961\u201370","key":"318_CR143","first-page":"e1","volume":"61","author":"MF Brin","year":"2009","unstructured":"Brin MF, Boodhoo TI, Pogoda JM, James LM, Demos G, Terashima Y, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009;61(961\u201370):e1\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"318_CR144","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/mds.20440","volume":"20","author":"T Mezaki","year":"2005","unstructured":"Mezaki T, Sakai R. Botulinum toxin and skin rash reaction. Mov Disord. 2005;20:770.","journal-title":"Mov Disord."},{"key":"318_CR145","doi-asserted-by":"crossref","unstructured":"Roehm PC, Perry JD, Girkin CA, Miller NR. Prevalence of periocular depigmentation after repeated botulinum toxin A injections in African American patients. J Neuro Ophthalmol. 1999;19:7\u20139.","DOI":"10.1097\/00041327-199903000-00002"},{"key":"318_CR146","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/dsu.12057","volume":"39","author":"TT Khan","year":"2013","unstructured":"Khan TT, Herne K, Dayan SH, Woodward JA. Facial blanching due to neurotoxins: proposed mechanisms. Dermatol Surg. 2013;39:24\u20139.","journal-title":"Dermatol Surg"},{"key":"318_CR147","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/0333102414544974","volume":"35","author":"PM Gadient","year":"2015","unstructured":"Gadient PM, Smith JH, Ryan SJ. Herpes zoster ophthalmicus following onabotulinumtoxinA administration for chronic migraine: a case report and literature review. Cephalalgia Int J Headache. 2015;35:443\u20138.","journal-title":"Cephalalgia Int J Headache"},{"key":"318_CR148","first-page":"49","volume":"4","author":"EM Graber","year":"2011","unstructured":"Graber EM, Dover JS, Arndt KA. Two cases of herpes zoster appearing after botulinum toxin type a injections. J Clin Aesthetic Dermatol. 2011;4:49\u201351.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"318_CR149","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMra052130","volume":"354","author":"EM Frohman","year":"2006","unstructured":"Frohman EM, Racke MK, Raine CS. Multiple sclerosis\u2014the plaque and its pathogenesis. N Engl J Med. 2006;354:942\u201355.","journal-title":"N Engl J Med"},{"key":"318_CR150","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","volume":"372","author":"A Compston","year":"2008","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet Lond Engl. 2008;372:1502\u201317.","journal-title":"Lancet Lond Engl"},{"key":"318_CR151","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883\u201397.","journal-title":"Nat Rev Drug Discov"},{"key":"318_CR152","unstructured":"Costello K, Halper J, Kalb R, Skutnik L, Rapp R. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A consensus paper by the multiple sclerosis coalition. Mult Scler Coalit. 2015;1\u201337."},{"key":"318_CR153","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1471-2377-13-146","volume":"13","author":"DMW Balak","year":"2013","unstructured":"Balak DMW, Hengstman GJD, Hajdarbegovic E, van den Brule RJP, Hupperts RMM, Thio HB. Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study. BMC Neurol. 2013;13:146.","journal-title":"BMC Neurol."},{"key":"318_CR154","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/1352458512438239","volume":"18","author":"DMW Balak","year":"2012","unstructured":"Balak DMW, Hengstman GJD, \u00c7akmak A, Thio HB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler. 2012;18:1705\u201317.","journal-title":"Mult Scler"},{"key":"318_CR155","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s004150050568","volume":"247","author":"GL Mancardi","year":"2000","unstructured":"Mancardi GL, Murialdo A, Drago F, Brusati C, Croce R, Inglese M, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol. 2000;247:220\u20131.","journal-title":"J Neurol"},{"key":"318_CR156","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1017\/S0317167100002845","volume":"31","author":"CM Edgar","year":"2004","unstructured":"Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci. 2004;31:58\u201363.","journal-title":"Can J Neurol Sci"},{"key":"318_CR157","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1600-0560.2007.00819.x","volume":"35","author":"NJ Ball","year":"2008","unstructured":"Ball NJ, Cowan BJ, Moore GRW, Hashimoto SA. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases. J Cutan Pathol. 2008;35:407\u201310.","journal-title":"J Cutan Pathol."},{"key":"318_CR158","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0190-9622(07)80010-7","volume":"34","author":"GF Webster","year":"1996","unstructured":"Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol. 1996;34:365\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"318_CR159","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0190-9622(97)70170-1","volume":"37","author":"GW Elgart","year":"1997","unstructured":"Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J Am Acad Dermatol. 1997;37:553\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"318_CR160","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1468-3083.2004.01086.x","volume":"19","author":"MG Ozden","year":"2005","unstructured":"Ozden MG, Erel A, Erdem O, Oztas MO. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient. J Eur Acad Dermatol Venereol JEADV. 2005;19:112\u20133.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"318_CR161","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1191\/1352458503ms933sr","volume":"9","author":"F Casoni","year":"2003","unstructured":"Casoni F, Merelli E, Bedin R, Martella A, Cesinaro A, Bertolotto A. Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b. Mult Scler. 2003;9:420\u20133.","journal-title":"Mult Scler"},{"key":"318_CR162","first-page":"774","volume":"25","author":"C-H Yang","year":"2002","unstructured":"Yang C-H, Chen CH, Chan H-L. Skin necrosis following a recombinant interferon-beta-1b injection. Chang Gung Med J. 2002;25:774\u20137.","journal-title":"Chang Gung Med J."},{"key":"318_CR163","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/00015550152384407","volume":"81","author":"M Garc\u00eda-F-Villalta","year":"2001","unstructured":"Garc\u00eda-F-Villalta M, Daud\u00e9n E, S\u00e1nchez J, Fraga J, Ramo C, Garc\u00eda-D\u00edez A. Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b. Acta Derm Venereol. 2001;81:152.","journal-title":"Acta Derm Venereol"},{"key":"318_CR164","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/jnnp.62.4.418","volume":"62","author":"C Albani","year":"1997","unstructured":"Albani C, Albani G. A case of cutaneous necrosis during interferon-beta 1b (B-IFN) therapy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;62:418.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"318_CR165","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/jnnp.68.3.395","volume":"68","author":"A Cr\u00e9ange","year":"2000","unstructured":"Cr\u00e9ange A, Lefaucheur JP. Focal neuropathy associated with cutaneous necrosis at the site of interferon-beta injection for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"318_CR166","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJM199506083322316","volume":"332","author":"WA Sheremata","year":"1995","unstructured":"Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med. 1995;332:1584.","journal-title":"N Engl J Med"},{"key":"318_CR167","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1346-8138.2009.00783.x","volume":"37","author":"U Ohata","year":"2010","unstructured":"Ohata U, Hara H, Yoshitake M, Terui T. Cutaneous reactions following subcutaneous beta-interferon-1b injection. J Dermatol. 2010;37:179\u201381.","journal-title":"J Dermatol"},{"key":"318_CR168","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000245687","volume":"195","author":"R Feldmann","year":"1997","unstructured":"Feldmann R, L\u00f6w-Weiser H, Duschet P, Gschnait F. Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. Dermatol Basel Switz. 1997;195:52\u20133.","journal-title":"Dermatol Basel Switz"},{"key":"318_CR169","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2340\/00015555577146148","volume":"77","author":"JM Weinberg","year":"1997","unstructured":"Weinberg JM, Wolfe JT, Sood S, Saruk M, Rook AH, Spiers EM. Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature. Acta Derm Venereol. 1997;77:146\u20138.","journal-title":"Acta Derm Venereol"},{"key":"318_CR170","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1007\/s00415-006-0233-9","volume":"253","author":"I Bosca","year":"2006","unstructured":"Bosca I, Bosca M, Belenguer A, Evole M, Hernandez M, Casanova B, et al. Necrotising cutaneous lesions as a side effect of glatiramer acetate. J Neurol. 2006;253:1370\u20131.","journal-title":"J Neurol"},{"key":"318_CR171","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1177\/1352458507079612","volume":"13","author":"D Koontz","year":"2007","unstructured":"Koontz D, Alshekhlee A. Embolia cutis medicamentosa following interferon beta injection. Mult Scler. 2007;13:1203\u20134.","journal-title":"Mult Scler"},{"key":"318_CR172","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1684\/ejd.2009.0675","volume":"19","author":"R Feldmann","year":"2009","unstructured":"Feldmann R, Schierl M, Rauschka H, Sator P-G, Breier F, Steiner A. Necrotizing skin lesions with involvement of muscle tissue after subcutaneous injection of glatiramer acetate. Eur J Dermatol EJD. 2009;19:385.","journal-title":"Eur J Dermatol EJD"},{"key":"318_CR173","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1610-0387.2007.06391.x","volume":"5","author":"V Harde","year":"2007","unstructured":"Harde V, Schwarz T. Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate. J Dtsch Dermatol Ges. 2007;5:1122\u20133.","journal-title":"J Dtsch Dermatol Ges."},{"key":"318_CR174","unstructured":"Gaudez C, Regnier S, Aractingi S, Heinzlef O. Livedo-like dermatitis (Nicolau\u2019s syndrome) after injection of Copolymer-1 (Glatiramer acetate). Rev Neurol (Paris). 2003;159:571\u20133."},{"key":"318_CR175","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/archderm.144.10.1341","volume":"144","author":"A-K Somani","year":"2008","unstructured":"Somani A-K, Swick AR, Cooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008;144:1341\u20139.","journal-title":"Arch Dermatol"},{"key":"318_CR176","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1177\/1352458507076385","volume":"13","author":"E Thouvenot","year":"2007","unstructured":"Thouvenot E, Hillaire-Buys D, Bos-Thompson MA, Rigau V, Durand L, Guillot B, et al. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Mult Scler. 2007;13:941\u20134.","journal-title":"Mult Scler"},{"key":"318_CR177","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1191\/1352458504ms987cr","volume":"10","author":"N Kumar","year":"2004","unstructured":"Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler. 2004;10:85\u20136.","journal-title":"Mult Scler"},{"key":"318_CR178","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jocn.2006.07.011","volume":"14","author":"T Gono","year":"2007","unstructured":"Gono T, Matsuda M, Shimojima Y, Kaneko K, Murata H, Ikeda S. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient. J Clin Neurosci. 2007;14:997\u20131000.","journal-title":"J Clin Neurosci"},{"key":"318_CR179","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1111\/j.1468-1331.2009.02563.x","volume":"16","author":"B Kocer","year":"2009","unstructured":"Kocer B, Nazliel B, Oztas M, Batur HZ. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report. Eur J Neurol. 2009;16:e78\u20139.","journal-title":"Eur J Neurol."},{"key":"318_CR180","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1191\/1352458505ms1130cr","volume":"11","author":"S Nolden","year":"2005","unstructured":"Nolden S, Casper C, Kuhn A, Petereit HF. Jessner\u2013Kanof lymphocytic infiltration of the skin associated with glatiramer acetate. Mult Scler. 2005;11:245\u20138.","journal-title":"Mult Scler"},{"key":"318_CR181","first-page":"62","volume":"43","author":"C Bayerl","year":"2000","unstructured":"Bayerl C, Bohland P, Jung EG. Systemic reaction to glatiramer acetate. Contact Dermatitis. 2000;43:62\u20133.","journal-title":"Contact Dermatitis."},{"key":"318_CR182","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1212\/01.WNL.0000158675.01711.58","volume":"64","author":"H Rauschka","year":"2005","unstructured":"Rauschka H, Farina C, Sator P, Gudek S, Breier F, Schmidbauer M. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology. 2005;64:1481\u20132.","journal-title":"Neurology."},{"key":"318_CR183","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.1365-2133.2003.50802.x","volume":"148","author":"L Mazzeo","year":"2003","unstructured":"Mazzeo L, Ricciardi L, Fazio MC, Fogliani O, Fedele R, Ferlazzo E, et al. Severe urticaria due to recombinant interferon beta-1a. Br J Dermatol. 2003;148:172.","journal-title":"Br J Dermatol"},{"key":"318_CR184","doi-asserted-by":"crossref","unstructured":"Fusun Kalpaklioglu A, Baccioglu Kavut A, Erdemoglu AK. Desensitization in interferon-beta1a allergy: a case report. Int. Arch Allergy Immunol. 2009;149:178\u201380.","DOI":"10.1159\/000189203"},{"key":"318_CR185","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10072-010-0432-0","volume":"32","author":"C Guijarro","year":"2011","unstructured":"Guijarro C, Benito-Le\u00f3n J, Bermejo-Pareja F. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis. Neurol Sci. 2011;32:309\u201311.","journal-title":"Neurol Sci."},{"key":"318_CR186","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1212\/WNL.56.10.1416-a","volume":"56","author":"DL Brown","year":"2001","unstructured":"Brown DL, Login IS, Borish L, Powers PL. An urticarial IgE-mediated reaction to interferon beta-1b. Neurology. 2001;56:1416\u20137.","journal-title":"Neurology."},{"key":"318_CR187","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med"},{"key":"318_CR188","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0190-9622(97)70154-3","volume":"37","author":"JE Fruland","year":"1997","unstructured":"Fruland JE, Sandermann S, Snow SN, Friedl A, Sharata HH. Skin necrosis with subsequent formation of squamous cell carcinoma after subcutaneous interferon beta injection. J Am Acad Dermatol. 1997;37:488\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"318_CR189","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue E-W, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545\u201356.","journal-title":"Lancet Neurol."},{"key":"318_CR190","first-page":"73","volume":"9","author":"C Gasperini","year":"2013","unstructured":"Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag. 2013;9:73\u201385.","journal-title":"Ther Clin Risk Manag"},{"key":"318_CR191","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387\u2013401.","journal-title":"N Engl J Med"},{"key":"318_CR192","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archdermatol.2011.212","volume":"147","author":"KB Conzett","year":"2011","unstructured":"Conzett KB, Kolm I, Jelcic I, Kamarachev J, Dummer R, Braun R, et al. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. Arch Dermatol. 2011;147:991.","journal-title":"Arch Dermatol"},{"key":"318_CR193","doi-asserted-by":"crossref","unstructured":"Cohen JA, Khatri B, Barkhof F, Comi G, Hartung H-P, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2015 (jnnp-2015-310597).","DOI":"10.1136\/jnnp-2015-310597"},{"key":"318_CR194","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/archneur.65.10.1378","volume":"65","author":"MM Madray","year":"2008","unstructured":"Madray MM, Greene JF, Butler DF. Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Neurol. 2008;65:1378\u20139.","journal-title":"Arch Neurol"},{"key":"318_CR195","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1440-0960.2005.00168.x","volume":"46","author":"YJ Tai","year":"2005","unstructured":"Tai YJ, Tam M. Fixed drug eruption with interferon-beta-1b. Australas J Dermatol. 2005;46:154\u20137.","journal-title":"Australas J Dermatol"},{"key":"318_CR196","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1352458507079945","volume":"14","author":"G Serarslan","year":"2008","unstructured":"Serarslan G, Okuyucu E, Melek I, Hakverdi S, Duman T. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis. Mult Scler. 2008;14:259\u201361.","journal-title":"Mult Scler"},{"key":"318_CR197","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S0190-9622(98)70285-3","volume":"39","author":"CL Mehta","year":"1998","unstructured":"Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol. 1998;39:1024\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"318_CR198","doi-asserted-by":"crossref","unstructured":"Ziegler VR, Kr\u00e4nke B, Soyer P, Aberer W. Extensive cutaneous-subcutaneous infiltration as a side-effect of interferon-beta injection. Hautarzt Z F\u00fcr Dermatol Venerol Verwandte Geb. 1998;49:310\u20132.","DOI":"10.1007\/s001050050747"},{"key":"318_CR199","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-2133.2007.08040.x","volume":"157","author":"AE Macbeth","year":"2007","unstructured":"Macbeth AE, Kendall BR, Smith A, Saldanha G, Harman KE. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy. Br J Dermatol. 2007;157:624\u20135.","journal-title":"Br J Dermatol"},{"key":"318_CR200","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/archneurol.2010.192","volume":"67","author":"MF Pacheco","year":"2010","unstructured":"Pacheco MF, Jacobe H, Eagar TN, St\u00fcve O. Reversible alopecia associated with glatiramer acetate. Arch Neurol. 2010;67:1154.","journal-title":"Arch Neurol."},{"key":"318_CR201","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","volume":"74","author":"A Bar-Or","year":"2014","unstructured":"Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74:659\u201374.","journal-title":"Drugs."},{"key":"318_CR202","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","volume":"13","author":"AE Miller","year":"2014","unstructured":"Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977\u201386.","journal-title":"Lancet Neurol."},{"issue":"11","key":"318_CR203","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1177\/1352458515596601","volume":"21","author":"G Gerschenfeld","year":"2015","unstructured":"Gerschenfeld G, Servy A, Valeyrie-Allanore L, de Prost N, Cecchini J. Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis. Mult Scler. 2015;21(11):1476\u20137.","journal-title":"Mult Scler."},{"key":"318_CR204","doi-asserted-by":"crossref","unstructured":"Xu Z, Zhang F, Sun F, Gu K, Dong S, He D. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev. 2015;4:CD011076.","DOI":"10.1002\/14651858.CD011076.pub2"},{"key":"318_CR205","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ana.22426","volume":"69","author":"JA Cohen","year":"2011","unstructured":"Cohen JA, Chun J. Mechanisms of fingolimod\u2019s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69:759\u201377.","journal-title":"Ann Neurol"},{"key":"318_CR206","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","volume":"78","author":"N Jain","year":"2012","unstructured":"Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78:672\u201380.","journal-title":"Neurology."},{"key":"318_CR207","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1177\/1352458514525872","volume":"20","author":"S Masera","year":"2014","unstructured":"Masera S, Chiavazza C, Mattioda A, Superti G, Beggiato E, Crosasso P, et al. Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod. Mult Scler. 2014;20:1666\u20137.","journal-title":"Mult Scler"},{"issue":"1","key":"318_CR208","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1352458515597568","volume":"22","author":"AP Samaraweera","year":"2015","unstructured":"Samaraweera AP, Cohen SN, Akay EM, Evangelou N. Lymphomatoid papulosis: a cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Mult Scler. 2015;22(1):122\u20134.","journal-title":"Mult Scler"},{"key":"318_CR209","doi-asserted-by":"publisher","first-page":"16414","DOI":"10.3390\/ijms160716414","volume":"16","author":"T Ruck","year":"2015","unstructured":"Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci. 2015;16:16414\u201339.","journal-title":"Int J Mol Sci"},{"key":"318_CR210","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet Lond Engl. 2012;380:1819\u201328.","journal-title":"Lancet Lond Engl."},{"key":"318_CR211","unstructured":"Wray S, Arnold DL, Cohen J, Coles A, Fox E, Hartung H. Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. In: Poster presented at the 2013 Annual Meeting of the Consortium for Multiple Sclerosis Centers, May 29-June 1, 2013, Orlando, FL. 2013."},{"key":"318_CR212","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1756285614563522","volume":"8","author":"E Havrdova","year":"2015","unstructured":"Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015;8:31\u201345.","journal-title":"Ther Adv Neurol Disord"},{"key":"318_CR213","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.0000000000000540","volume":"83","author":"T Menge","year":"2014","unstructured":"Menge T, St\u00fcve O, Kieseier BC, Hartung H-P. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology. 2014;83:87\u201397.","journal-title":"Neurology."},{"key":"318_CR214","first-page":"25","volume":"5","author":"R Planas","year":"2014","unstructured":"Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas. 2014;5:25\u201333.","journal-title":"Patient Relat Outcome Meas."},{"key":"318_CR215","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","volume":"83","author":"P O\u2019Connor","year":"2014","unstructured":"O\u2019Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83:78\u201386.","journal-title":"Neurology."},{"key":"318_CR216","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0b013e3181cef810","volume":"74","author":"S Gutwinski","year":"2010","unstructured":"Gutwinski S, Erbe S, M\u00fcnch C, Janke O, M\u00fcller U, Haas J. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology. 2010;74:521\u20133.","journal-title":"Neurology."},{"key":"318_CR217","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/archneur.64.9.1331","volume":"64","author":"M Krumbholz","year":"2007","unstructured":"Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, K\u00fcmpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007;64:1331\u20133.","journal-title":"Arch Neurol"},{"key":"318_CR218","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.clinthera.2012.03.007","volume":"34","author":"DR Cornblath","year":"2012","unstructured":"Cornblath DR, Bienen EJ, Blight AR. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clin Ther. 2012;34:1056\u201369.","journal-title":"Clin Ther"},{"key":"318_CR219","doi-asserted-by":"publisher","unstructured":"Turnbull K, Caslake R, Macleod AD, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005;(3):CD004898. doi:10.1002\/14651858.CD004898.pub2.","DOI":"10.1002\/14651858.CD004898.pub2"},{"key":"318_CR220","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00002826-200009000-00006","volume":"23","author":"JL Montastruc","year":"2000","unstructured":"Montastruc JL, Chaumerliac C, Desboeuf K, Manika M, Bagheri H, Rascol O, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol. 2000;23:271\u20135.","journal-title":"Clin Neuropharmacol."},{"key":"318_CR221","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","volume":"59","author":"Parkinson Study Group","year":"2002","unstructured":"Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937\u201343.","journal-title":"Arch Neurol"},{"key":"318_CR222","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241\u20138.","journal-title":"Arch Neurol"},{"key":"318_CR223","unstructured":"Teva Pharmaceutical Industries Ltd. Azilect(R) package insert. Kfar Saba, Israel: Teva Pharmaceutical Industries Ltd; 2006."},{"key":"318_CR224","volume-title":"Mirapex(R) package insert","author":"Boehringer Ingelheim International GmbH","year":"2006","unstructured":"Boehringer Ingelheim International GmbH. Mirapex(R) package insert. Ridgefield: Boehringer Ingelheim International GmbH; 2006."},{"key":"318_CR225","unstructured":"GlaxoSmithKline. Requip(R) package insert. Research Triangle Park: GlaxoSmithKline; 2005."},{"key":"318_CR226","volume-title":"Zelapar(R) package insert","author":"Valeant Pharmaceuticals International","year":"2006","unstructured":"Valeant Pharmaceuticals International. Zelapar(R) package insert. Costa Mesa: Valeant Pharmaceuticals International; 2006."},{"key":"318_CR227","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/mds.22855","volume":"25","author":"JJ Ferreira","year":"2010","unstructured":"Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, et al. Skin cancer and Parkinson\u2019s disease. Mov Disord. 2010;25:139\u201348.","journal-title":"Mov Disord"},{"key":"318_CR228","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.parkreldis.2009.05.002","volume":"15","author":"J-D Vermeij","year":"2009","unstructured":"Vermeij J-D, Winogrodzka A, Trip J, Weber WEJ. Parkinson\u2019s disease, levodopa-use and the risk of melanoma. Parkinsonism Relat. Disord. 2009;15:551\u20133.","journal-title":"Parkinsonism Relat. Disord."},{"key":"318_CR229","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0733-8635(18)30506-0","volume":"8","author":"AB Fleischer","year":"1990","unstructured":"Fleischer AB, Resnick SD. Livedo reticularis. Dermatol Clin. 1990;8:347\u201354.","journal-title":"Dermatol Clin"},{"key":"318_CR230","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.jaad.2004.11.051","volume":"52","author":"MB Gibbs","year":"2005","unstructured":"Gibbs MB, English JC, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol. 2005;52:1009\u201319.","journal-title":"J Am Acad Dermatol"},{"key":"318_CR231","first-page":"764","volume":"11","author":"LC Strowd","year":"2012","unstructured":"Strowd LC, Lee AD, Yosipovitch G. Livedo reticularis associated with rasagiline (azilect). J Drugs Dermatol JDD. 2012;11:764\u20135.","journal-title":"J Drugs Dermatol JDD"},{"key":"318_CR232","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1590\/abd1806-4841.20153394","volume":"90","author":"MV Quaresma","year":"2015","unstructured":"Quaresma MV, Gomes ACD, Serruya A, Vendramini DL, Braga L, Bu\u00e7ard AM. Amantadine-induced livedo reticularis\u2014case report. An Bras Dermatol. 2015;90:745\u20137.","journal-title":"An Bras Dermatol"},{"key":"318_CR233","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/mds.20471","volume":"20","author":"C Singer","year":"2005","unstructured":"Singer C, Papapetropoulos S, Gonzalez MA, Roberts EL, Lieberman A. Rimantadine in Parkinson\u2019s disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Mov Disord. 2005;20:873\u20137.","journal-title":"Mov Disord."},{"key":"318_CR234","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/bmj.2.5762.627","volume":"2","author":"DI Vollum","year":"1971","unstructured":"Vollum DI, Parkes JD, Doyle D. Livedo reticularis during amantadine treatment. Br Med J. 1971;2:627\u20138.","journal-title":"Br Med J"},{"key":"318_CR235","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1046\/j.1365-2133.2003.05479.x","volume":"149","author":"MJ Sladden","year":"2003","unstructured":"Sladden MJ, Nicolaou N, Johnston GA, Hutchinson PE. Livedo reticularis induced by amantadine. Br J Dermatol. 2003;149:656\u20138.","journal-title":"Br J Dermatol"},{"key":"318_CR236","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/00207454.2012.668727","volume":"122","author":"AQ Rana","year":"2012","unstructured":"Rana AQ, Masroor MS. Patient perception of Levido reticularis due to amantadine. Int J Neurosci. 2012;122:363\u20136.","journal-title":"Int J Neurosci"},{"key":"318_CR237","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNF.0000000000000008","volume":"37","author":"K Eggert","year":"2014","unstructured":"Eggert K, Oertel WH, Lees AJ. German competence network on Parkinson\u2019s disease. Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study. Clin Neuropharmacol. 2014;37:1\u20135.","journal-title":"Clin Neuropharmacol."},{"key":"318_CR238","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/wnf.0b013e318038d2b6","volume":"30","author":"CW Olanow","year":"2007","unstructured":"Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007;30:287\u201394.","journal-title":"Clin Neuropharmacol."},{"key":"318_CR239","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","volume":"61","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61:1563.","journal-title":"Arch Neurol"},{"key":"318_CR240","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-4632.2004.02081.x","volume":"43","author":"C Foti","year":"2004","unstructured":"Foti C, Cassano N, De Mari M, Sorino M, Vena GA. Bullous skin eruption associated with entacapone. Int J Dermatol. 2004;43:471\u20132.","journal-title":"Int J Dermatol"},{"key":"318_CR241","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/WNF.0b013e31825c034a","volume":"35","author":"SZ Marsala","year":"2012","unstructured":"Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M. A systematic review of catechol-O-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol. 2012;35:185\u201390.","journal-title":"Clin Neuropharmacol."},{"key":"318_CR242","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/ane.12278","volume":"130","author":"M Kuoppam\u00e4ki","year":"2014","unstructured":"Kuoppam\u00e4ki M, Vahteristo M, Ellm\u00e9n J, Kieburtz K. Pooled analysis of phase III with entacapone in Parkinson\u2019s disease. Acta Neurol Scand. 2014;130:239\u201347.","journal-title":"Acta Neurol Scand"},{"key":"318_CR243","doi-asserted-by":"publisher","first-page":"190","DOI":"10.12816\/0003222","volume":"13","author":"HH Elahmed","year":"2013","unstructured":"Elahmed HH. Phototoxic rash during therapy with pramipexole in a patient with restless Legs syndrome. Sultan Qaboos Univ Med J. 2013;13:190\u20131.","journal-title":"Sultan Qaboos Univ Med J."},{"key":"318_CR244","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archneur.57.5.729","volume":"57","author":"EK Tan","year":"2000","unstructured":"Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol. 2000;57:729\u201332.","journal-title":"Arch Neurol"},{"issue":"1","key":"318_CR245","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/00207454.2014.991924","volume":"126","author":"CW Makumi","year":"2016","unstructured":"Makumi CW, Asgharian A, Ellis J, Shaikh S, Jimenez T, VanMeter S. Long-term, open-label, safety study of once-daily ropinirole extended\/prolonged release in early and advanced Parkinson\u2019s disease. Int J Neurosci. 2016;126(1):30\u20138.","journal-title":"Int J Neurosci"},{"key":"318_CR246","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351:2498\u2013508.","journal-title":"N Engl J Med"},{"key":"318_CR247","first-page":"1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044\u201353.","journal-title":"Arch Neurol"},{"key":"318_CR248","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484\u201391.","journal-title":"N Engl J Med"},{"key":"318_CR249","first-page":"1387","volume":"309","author":"CG Goetz","year":"1983","unstructured":"Goetz CG. Skin rash associated with Sinemet 25\/100. N Engl J Med. 1983;309:1387\u20138.","journal-title":"N Engl J Med"},{"key":"318_CR250","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1212\/01.wnl.0000257823.27573.3d","volume":"68","author":"KL Chou","year":"2007","unstructured":"Chou KL, Stacy MA. Skin rash associated with Sinemet does not equal levodopa allergy. Neurology. 2007;68:1078\u20139.","journal-title":"Neurology."},{"key":"318_CR251","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1212\/WNL.0b013e31821e554e","volume":"76","author":"R Liu","year":"2011","unstructured":"Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011;76:2002\u20139.","journal-title":"Neurology."},{"key":"318_CR252","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40120-014-0018-5","volume":"3","author":"EP Pioro","year":"2014","unstructured":"Pioro EP. Review of dextromethorphan 20\u00a0mg\/quinidine 10\u00a0mg (NUEDEXTA\u00ae) for Pseudobulbar affect. Neurol Ther. 2014;3:15\u201328.","journal-title":"Neurol Ther"},{"key":"318_CR253","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/NDT.S30713","volume":"10","author":"KA Schoedel","year":"2014","unstructured":"Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan\/quinidine in the treatment of pseudobulbar affect. Neuropsychiatr Dis Treat. 2014;10:1161\u201374.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"318_CR254","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0033-0620(77)90004-4","volume":"20","author":"IS Cohen","year":"1977","unstructured":"Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis. 1977;20:151\u201363.","journal-title":"Prog Cardiovasc Dis"},{"key":"318_CR255","first-page":"425","volume":"57","author":"EA Conroy","year":"1996","unstructured":"Conroy EA, Liranzo MO, McMahon J, Steck WD, Tuthill RJ. Quinidine-induced pigmentation. Cutis. 1996;57:425\u20137.","journal-title":"Cutis."},{"key":"318_CR256","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/archderm.1986.01660210112031","volume":"122","author":"R Mahler","year":"1986","unstructured":"Mahler R, Sissons W, Watters K. Pigmentation induced by quinidine therapy. Arch Dermatol. 1986;122:1062\u20134.","journal-title":"Arch Dermatol"},{"key":"318_CR257","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0030-4220(88)90067-9","volume":"66","author":"C Birek","year":"1988","unstructured":"Birek C, Main JH. Two cases of oral pigmentation associated with quinidine therapy. Oral Surg Oral Med Oral Pathol. 1988;66:59\u201361.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"318_CR258","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2165\/11588500-000000000-00000","volume":"34","author":"C Chang","year":"2011","unstructured":"Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34:357\u201374.","journal-title":"Drug Saf."},{"key":"318_CR259","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1001\/archinte.1985.00360110125026","volume":"145","author":"M Shalit","year":"1985","unstructured":"Shalit M, Flugelman MY, Harats N, Galun E, Ackerman Z, Kopolovic J, et al. Quinidine-induced vasculitis. Arch Intern Med. 1985;145:2051\u20132.","journal-title":"Arch Intern Med"},{"key":"318_CR260","first-page":"615","volume":"16","author":"RJ Holt","year":"1982","unstructured":"Holt RJ. Uncharacteristic cutaneous reactions induced by quinidine. Drug Intell Clin Pharm. 1982;16:615\u20136.","journal-title":"Drug Intell Clin Pharm"},{"key":"318_CR261","first-page":"38","volume":"66","author":"MC Adornato","year":"2000","unstructured":"Adornato MC. Toxic epidermal necrolysis associated with quinidine administration. N Y State Dent J. 2000;66:38\u201340.","journal-title":"N Y State Dent J"},{"key":"318_CR262","doi-asserted-by":"crossref","unstructured":"Otero Rivas MM, S\u00e1nchez Sambucety P, Garc\u00eda-Ruiz de Morales JM, P\u00e9rez Paredes G, Rodr\u00edguez Prieto MA. Acute generalized exanthematous pustulosis due to dextromethorphan. Dermatol Online J. 2013;19:20030.","DOI":"10.5070\/D31910020030"},{"key":"318_CR263","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1185\/03007995.2014.940040","volume":"30","author":"GL Pattee","year":"2014","unstructured":"Pattee GL, Wymer JP, Lomen-Hoerth C, Appel SH, Formella AE, Pope LE. An open-label multicenter study to assess the safety of dextromethorphan\/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin. 2014;30:2255\u201365.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"318_CR264","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40257-015-0158-0","volume":"16","author":"RP Dodiuk-Gad","year":"2015","unstructured":"Dodiuk-Gad RP, Chung W-H, Valeyrie-Allanore L, Shear NH. Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16(6):475\u201393.","journal-title":"Am J Clin Dermatol."},{"key":"318_CR265","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1017\/S1481803500011283","volume":"11","author":"TF Bruno","year":"2009","unstructured":"Bruno TF, Grewal P. Erythroderma: a dermatologic emergency. CJEM. 2009;11:244\u20136.","journal-title":"CJEM."},{"key":"318_CR266","doi-asserted-by":"crossref","unstructured":"Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68:709.e1\u20139 (quiz 718\u201320).","DOI":"10.1016\/j.jaad.2013.01.032"},{"key":"318_CR267","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","volume":"73","author":"J Szatkowski","year":"2015","unstructured":"Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73:843\u20138.","journal-title":"J Am Acad Dermatol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0318-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-016-0318-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0318-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0318-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T14:21:34Z","timestamp":1748787694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-016-0318-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,25]]},"references-count":267,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0318-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,25]]},"assertion":[{"value":"25 February 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eman Bahrani, Chloe E. Nunneley, Sylvia Hsu, and Joseph S. Kass have no financial or other relationships that might lead to a conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}